Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy.

Prelaj A, Rebuzzi SE, Pizzutilo P, Bilancia M, Montrone M, Pesola F, Longo V, Del Bene G, Lapadula V, Cassano F, Petrillo P, Bafunno D, Varesano N, Lamorgese V, Mastrandrea A, Ricci D, Catino A, Galetta D.

Clin Lung Cancer. 2020 Mar 7. pii: S1525-7304(19)30334-1. doi: 10.1016/j.cllc.2019.11.017. [Epub ahead of print]

PMID:
32245624
2.

Peripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients.

Prelaj A, Rebuzzi SE, Pizzutilo P, Bilancia M, Montrone M, Pesola F, Longo V, Del Bene G, Lapadula V, Cassano F, Petrillo P, Bafunno D, Varesano N, Lamorgese V, Mastranrdea A, Ricci D, Catino A, Galetta D.

Ann Oncol. 2019 Apr;30 Suppl 2:ii58. doi: 10.1093/annonc/mdz063.054. No abstract available.

3.

Time-series of peripheral blood biomarkers as biomarkers for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients.

Prelaj A, Rebuzzi SE, Pizzutilo P, Bilancia M, Montrone M, Pesola F, Longo V, Del Bene G, Lapadula V, Cassano F, Petrillo P, Bafunno D, Varesano N, Lamorgese V, Mastranrdea A, Ricci D, Catino A, Galetta D.

Ann Oncol. 2019 Apr;30 Suppl 2:ii34. doi: 10.1093/annonc/mdz067.004. No abstract available.

4.

Engaging Students and Pharmacists in Medical Missions.

Talagtag M, Petrillo PT, Lajoie K, Chahine EB.

Sr Care Pharm. 2019 Jul 1;34(7):444-448. doi: 10.4140/TCP.n.2019.444..

PMID:
31383055
5.

Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial.

Santo A, Pilotto S, Galetta D, Grossi F, Fasola G, Romano G, Bonanno L, Bearz A, Papi M, Roca E, Catino A, Follador A, Rijavec E, Genova C, Petrillo P, Favaretto A, Giannone L, Milella M, Tortora G, Giannarelli D, Bria E; Italian association FONICAP (Operative National Interdisciplinary Force against Lung Cancer).

Lung Cancer. 2019 Aug;134:121-126. doi: 10.1016/j.lungcan.2019.06.011. Epub 2019 Jun 11.

PMID:
31319970
6.

Tobacco control in Europe: A review of campaign strategies for teenagers and adults.

Bafunno D, Catino A, Lamorgese V, Pizzutilo P, Di Lauro A, Petrillo P, Lapadula V, Mastrandrea A, Ricci D, Galetta D.

Crit Rev Oncol Hematol. 2019 Jun;138:139-147. doi: 10.1016/j.critrevonc.2019.01.022. Epub 2019 Apr 2. Review.

PMID:
31092369
7.

Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer.

Gobbini E, Pilotto S, Pasello G, Polo V, Di Maio M, Arizio F, Galetta D, Petrillo P, Chiari R, Matocci R, Di Costanzo A, Di Stefano TS, Aglietta M, Cagnazzo C, Sperduti I, Bria E, Novello S.

Clin Lung Cancer. 2018 Mar;19(2):191-198. doi: 10.1016/j.cllc.2017.10.012. Epub 2017 Oct 28.

PMID:
29153968
8.

Challenges and opportunities of microRNAs in lymphomas.

De Tullio G, De Fazio V, Sgherza N, Minoia C, Serratì S, Merchionne F, Loseto G, Iacobazzi A, Rana A, Petrillo P, Silvestris N, Iacopino P, Guarini A.

Molecules. 2014 Sep 17;19(9):14723-81. doi: 10.3390/molecules190914723. Review.

9.

Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.

Marti M, Mela F, Budri M, Volta M, Malfacini D, Molinari S, Zaveri NT, Ronzoni S, Petrillo P, Calò G, Morari M.

Br J Pharmacol. 2013 Feb;168(4):863-79. doi: 10.1111/j.1476-5381.2012.02219.x.

10.

Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist.

Villetti G, Pastore F, Bergamaschi M, Bassani F, Bolzoni PT, Battipaglia L, Amari G, Rizzi A, Delcanale M, Volta R, Cenacchi V, Cacciani F, Zaniboni M, Berti F, Rossoni G, Harrison S, Petrillo P, Santoro E, Scudellaro R, Mannini F, Geppetti PA, Razzetti R, Patacchini R, Civelli M.

J Pharmacol Exp Ther. 2010 Dec;335(3):622-35. doi: 10.1124/jpet.110.170035. Epub 2010 Aug 30.

PMID:
20805306
11.

Spleen tyrosine kinases: biology, therapeutic targets and drugs.

Riccaboni M, Bianchi I, Petrillo P.

Drug Discov Today. 2010 Jul;15(13-14):517-30. doi: 10.1016/j.drudis.2010.05.001. Epub 2010 May 27. Review.

PMID:
20553955
12.

Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists.

Peretto I, Petrillo P, Imbimbo BP.

Med Res Rev. 2009 Nov;29(6):867-902. doi: 10.1002/med.20158. Review.

PMID:
19399831
13.

Synthesis and biological evaluation of novel dimiracetam derivatives useful for the treatment of neuropathic pain.

Farina C, Gagliardi S, Ghelardini C, Martinelli M, Norcini M, Parini C, Petrillo P, Ronzoni S.

Bioorg Med Chem. 2008 Mar 15;16(6):3224-32. doi: 10.1016/j.bmc.2007.12.015. Epub 2007 Dec 15.

PMID:
18171618
14.

Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 2).

Peretto I, Fossati C, Giardina GA, Giardini A, Guala M, La Porta E, Petrillo P, Radaelli S, Radice L, Raveglia LF, Santoro E, Scudellaro R, Scarpitta F, Cerri A, Menegon S, Dondio GM, Rizzi A, Armani E, Amari G, Civelli M, Villetti G, Patacchini R, Bergamaschi M, Bassani F, Delcanale M, Imbimbo BP.

J Med Chem. 2007 Apr 5;50(7):1693-7. Epub 2007 Mar 13.

PMID:
17352463
15.

Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1).

Peretto I, Forlani R, Fossati C, Giardina GA, Giardini A, Guala M, La Porta E, Petrillo P, Radaelli S, Radice L, Raveglia LF, Santoro E, Scudellaro R, Scarpitta F, Bigogno C, Misiano P, Dondio GM, Rizzi A, Armani E, Amari G, Civelli M, Villetti G, Patacchini R, Bergamaschi M, Delcanale M, Salcedo C, Fernández AG, Imbimbo BP.

J Med Chem. 2007 Apr 5;50(7):1571-83. Epub 2007 Mar 13.

PMID:
17352462
16.

Laparoscopic procedures for colorectal cancer: analysis of 134 cases.

Antropoli M, Di Palma D, Tufo P, Lanni R, Petrillo P, Berruti G, Frattolillo FM.

Chir Ital. 2006 Jan-Feb;58(1):77-82.

PMID:
16729613
17.

The effects of fluoxetine and buspirone on self-injurious and stereotypic behavior in adult male rhesus macaques.

Fontenot MB, Padgett EE 3rd, Dupuy AM, Lynch CR, De Petrillo PB, Higley JD.

Comp Med. 2005 Feb;55(1):67-74.

PMID:
15766212
18.

Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111).

Zaratin PF, Petrone G, Sbacchi M, Garnier M, Fossati C, Petrillo P, Ronzoni S, Giardina GA, Scheideler MA.

J Pharmacol Exp Ther. 2004 Feb;308(2):454-61. Epub 2003 Oct 30.

PMID:
14593080
19.
20.

Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists.

Blaney FE, Raveglia LF, Artico M, Cavagnera S, Dartois C, Farina C, Grugni M, Gagliardi S, Luttmann MA, Martinelli M, Nadler GM, Parini C, Petrillo P, Sarau HM, Scheideler MA, Hay DW, Giardina GA.

J Med Chem. 2001 May 24;44(11):1675-89.

PMID:
11356103
21.

Selective delta opioid receptor agonists for inflammatory and neuropathic pain.

Dondio G, Ronzoni S, Farina C, Graziani D, Parini C, Petrillo P, Giardina GA.

Farmaco. 2001 Jan-Feb;56(1-2):117-9.

PMID:
11347951
22.

Synthesis and NMR characterization of a novel class of thienomorphinans.

Ronzoni S, Cerri A, Dondio G, Fronza G, Petrillo P, Raveglia LF, Gatti PA.

Org Lett. 1999 Aug 12;1(3):513-5.

PMID:
10822591
23.

The antitussive activity of delta-opioid receptor stimulation in guinea pigs.

Kotzer CJ, Hay DW, Dondio G, Giardina G, Petrillo P, Underwood DC.

J Pharmacol Exp Ther. 2000 Feb;292(2):803-9.

PMID:
10640321
24.

Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective delta opioid agonists, based on an extension of the message-address concept.

Dondio G, Ronzoni S, Eggleston DS, Artico M, Petrillo P, Petrone G, Visentin L, Farina C, Vecchietti V, Clarke GD.

J Med Chem. 1997 Sep 26;40(20):3192-8.

PMID:
9379438
25.
26.

Characterization of opioid binding sites in rat spinal cord.

Petrillo P, Kowalski J, Sbacchi M, Tavani A.

J Recept Res. 1992;12(1):39-57.

PMID:
1314311
27.

The TELECOS project: experience of the Basilicata region.

Petrillo P, Loiudice V, Tafuni D.

Rays. 1991 Oct-Dec;16(4):436-51. English, Italian. No abstract available.

PMID:
1788410
28.

In vitro binding profile and in vivo pharmacological properties of the K-opioid compound PD 117302.

Colombo M, Petrillo P, La Regina A, Bianchi G, Tavani A.

Res Commun Chem Pathol Pharmacol. 1991 Jun;72(3):295-306.

PMID:
1658887
29.

Role of peripheral mu, delta and kappa opioid receptors in opioid-induced inhibition of gastrointestinal transit in rats.

Tavani A, Petrillo P, La Regina A, Sbacchi M.

J Pharmacol Exp Ther. 1990 Jul;254(1):91-7.

PMID:
2164103
30.

Regional variations in binding capacities at mu-, delta- and kappa-opioid sites in membrane suspensions from rabbit brain.

Petrillo P, La Regina A, Sbacchi M, Tavani A, Robson LE, Kosterlitz HW.

Eur J Pharmacol. 1989 Jul 18;166(2):213-7.

PMID:
2551699
31.
32.

D-optimal design applied to binding saturation curves of an enkephalin analog in rat brain.

Verotta D, Petrillo P, La Regina A, Rocchetti M, Tavani A.

Life Sci. 1988;42(6):735-43.

PMID:
2828802
33.
34.

Dopamine denervation of the nucleus accumbens induces a selective increase in the number of delta-opioid binding sites.

Esposito E, Cervo L, Petrillo P, Sbacchi M, Tavani A, Samanin R.

Brain Res. 1987 Dec 8;436(1):25-9.

PMID:
2825926
35.

Differential postnatal development of mu-, delta- and kappa-opioid binding sites in rat brain.

Petrillo P, Tavani A, Verotta D, Robson LE, Kosterlitz HW.

Brain Res. 1987 Jan;428(1):53-8.

PMID:
3815117
36.

The role of mu- and delta- opioid receptors on the intestinal propulsion in rats.

Sbacchi M, La Regina A, Petrillo P, Tavani A.

NIDA Res Monogr. 1986;75:520-3.

PMID:
2828999
38.

Central and peripheral inhibition of gastrointestinal transit in rats: narcotics differ substantially by acting at either or both levels.

Peracchia F, Bianchi G, Fiocchi R, Petrillo P, Tavani A, Manara L.

J Pharm Pharmacol. 1984 Oct;36(10):699-701.

PMID:
6150093
40.

The opioid kappa-selective compound U-50,488H does not inhibit intestinal propulsion in rats.

Tavani A, Gambino MC, Petrillo P.

J Pharm Pharmacol. 1984 May;36(5):343-4.

PMID:
6145777
41.
42.
43.

Morphine inhibits gastrointestinal transit in the rat primarily by impairing propulsive activity of the small intestine.

Fiocchi R, Bianchi G, Petrillo P, Tavani A, Manara L.

Life Sci. 1982 Nov 15-22;31(20-21):2221-3.

PMID:
7162339
44.

[Ketalar as an anesthetic in adenotonsillectomy].

Bruno V, D'Auria C, Petrillo P, Andrisani I.

Minerva Med. 1977 Jan 21;68(3):179-81. Italian. No abstract available.

PMID:
840411
45.

[Dissociative anesthesia with ketamine. Clinical contribution].

D'Auria C, Petrillo P, Andrisani I, Bruno V, Montemurro D.

Minerva Med. 1977 Jan 21;68(3):187-90. Italian. No abstract available.

PMID:
583640
46.

[Analgesimetry after ethrane anesthesia].

D'Auria C, Petrillo P, Bruno V, Andrisani I.

Minerva Anestesiol. 1975 Oct;41(10):459-63. Italian. No abstract available.

PMID:
1230659

Supplemental Content

Loading ...
Support Center